Chemicals & Pharmaceuticals CEO pay ratio
SEC EDGAR DEF 14A benchmarks for SIC 28. Highest in-industry ratio on this page: Keenova Therapeutics plc at 435:1.
- Median pay ratio
- 42:1
- Average pay ratio
- 74:1
- Median CEO pay
- $7.9M
- Companies tracked
- 168
Data updated August 2026
Answer first
Chemicals & Pharmaceuticals sits at #63 of 63 SIC-2 industries by median CEO-to-worker pay ratio and #35 of 63 by median CEO pay - ratio rank is not dollar rank (168 FY2025 filers, median 42:1 / $7.9M).
Placement uses the same latest-fiscal-year-per-SIC medians as the Industries directory. Median-ratio rank #63 of 63 is not median-CEO-pay rank #35 of 63. Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. Inside this SIC, Keenova Therapeutics plc currently leads the in-page company list at 435:1.
- Median ratio
- 42:1
- #63 of 63 SIC-2 industries
- Median CEO pay
- $7.9M
- #35 of 63 by median dollars
- Filers
- 168
- FY2025 SIC 28
Ratio bands inside Chemicals & Pharmaceuticals
Exclusive CEO-to-median-worker bands across 153 complete FY2025 filings in SIC 28. Segments sum to the in-industry set, not the leader bars below.
Chemicals & Pharmaceuticals vs all SIC-2 industries
Unique-issuer pay ratios in this SIC as bars , plus live COUNT placement #63 of 63 industries by median CEO-to-worker pay ratio (2nd percentile) . Corpus complete-filing median is 87:1; this industry's median is 42:1.
Filing-year trail · SIC 28
Same SIC-2 industry_benchmarks extract across FY2021–2025: median CEO-to-worker pay ratio, median CEO dollars, and filer count per fiscal year. Year-over-year deltas compare adjacent filing years only; they are not inflation-adjusted and do not invent missing years.
- Latest median ratio
- 42:1
- FY2025
- vs prior FY
- +1:1
- from FY2024 41:1
- Median CEO $ YoY
- +10%
- $7.9M latest
- Filer count YoY
- -29
- 168 in FY2025
| FY | Median ratio | Δ ratio | Median CEO pay | Δ pay | Filers |
|---|---|---|---|---|---|
| 2021 | 44:1 | - | $6.0M | - | 179 |
| 2022 | 38:1 | -6:1 | $6.6M | +8.5% | 202 |
| 2023 | 44:1 | +6:1 | $7.3M | +11% | 187 |
| 2024 | 41:1 | -3:1 | $7.2M | -1.7% | 197 |
| 2025 | 42:1 | +1:1 | $7.9M | +10% | 168 |
Source: PlainCEOPay industry_benchmarks for SIC 28 (Chemicals & Pharmaceuticals), FY2021–2025. Each row is one fiscal-year cohort median, not a company-level panel.
Lower-third median pay ratio
Chemicals & Pharmaceuticals in the lower-ratio third
Chemicals & Pharmaceuticals sits in the bottom third of SIC-2 industries by median CEO-to-worker pay ratio (42:1; #63 of 63). Chemicals & Pharmaceuticals (SIC 28) posts a lower-third median CEO-to-worker pay ratio of 42:1 across 168 FY2025 SEC filers.
Even in the lower-ratio third, the 25th percentile CEO earned $3.6M while the 75th earned $14.6M. The 74:1 average sits well above the 42:1 median, so a few very-high-pay CEOs are pulling the mean; the median is the fairer yardstick.
Below: each of the 299 Chemicals & Pharmaceuticals companies PlainCEOPay tracks in this SIC , with CEO total compensation, median worker pay, and pay ratios. Company pages compare each filing to this industry median. Figures are from SEC EDGAR filings - not estimates.
According to the U.S. Securities and Exchange Commission's EDGAR database, PlainCEOPay's August 2026 refresh processed 2,456 public companies with 1,423 complete FY2025 DEF 14A proxy filings (fiscal years 2021 through 2025) under Item 402(u) of Regulation S-K. See our methodology for parsing rules.
Companies in Chemicals & Pharmaceuticals (299 )
| # | Company | CEO Pay | Median Worker | Pay Ratio | FY |
|---|---|---|---|---|---|
| 1 | Enanta Pharmaceuticals Inc Latest filing FY2024 SEC EDGAR DEF 14A, CIK 1177648 | $2.7M | $208K | 2,023:1 | 2024 |
| 2 | Danimer Scientific, Inc. Latest filing FY2021 SEC EDGAR DEF 14A, CIK 1779020 | $71.9M | $58K | 1,232:1 | 2021 |
| 3 | Roivant Sciences Ltd. Latest filing FY2024 SEC EDGAR DEF 14A, CIK 1635088 | $163.4M | $315K | 518:1 | 2024 |
| 4 | Endo International plc Latest filing FY2021 SEC EDGAR DEF 14A, CIK 1593034 | $29.0M | $66K | 441:1 | 2021 |
| 5 | Keenova Therapeutics plc SEC EDGAR DEF 14A, CIK 1567892 | $47.4M | $109K | 435:1 | 2025 |
| 6 | Linde PLC SEC EDGAR DEF 14A, CIK 1707925 | $21.8M | $51K | 428:1 | 2025 |
| 7 | Coty Inc. Latest filing FY2024 SEC EDGAR DEF 14A, CIK 1024305 | $19.7M | $48K | 412:1 | 2024 |
| 8 | Bausch Health Companies Inc. SEC EDGAR DEF 14A, CIK 885590 | $16.9M | $42K | 401:1 | 2025 |
| 9 | Estee Lauder Companies Inc Latest filing FY2024 SEC EDGAR DEF 14A, CIK 1001250 | $13.4M | $38K | 352:1 | 2024 |
| 10 | Ppg Industries Inc SEC EDGAR DEF 14A, CIK 79879 | $16.6M | $47K | 352:1 | 2025 |
| 11 | Viatris Inc SEC EDGAR DEF 14A, CIK 1792044 | $15.3M | $47K | 327:1 | 2025 |
| 12 | ELI LILLY & Co SEC EDGAR DEF 14A, CIK 59478 | $36.7M | $125K | 293:1 | 2025 |
| 13 | Pfizer Inc SEC EDGAR DEF 14A, CIK 78003 | $27.6M | $100K | 277:1 | 2025 |
| 14 | PROCTER & GAMBLE Co Latest filing FY2024 SEC EDGAR DEF 14A, CIK 80424 | $21.9M | $80K | 276:1 | 2024 |
| 15 | Tilray Brands, Inc. Latest filing FY2024 SEC EDGAR DEF 14A, CIK 1731348 | $10.3M | $39K | 266:1 | 2024 |
| 16 | Harrow, Inc. SEC EDGAR DEF 14A, CIK 1360214 | $23.6M | $90K | 263:1 | 2025 |
| 17 | Teva Pharmaceutical Industries Ltd SEC EDGAR DEF 14A, CIK 818686 | $19.2M | $75K | 257:1 | 2025 |
| 18 | Seagen Inc. Latest filing FY2022 SEC EDGAR DEF 14A, CIK 1060736 | $57.5M | $226K | 254:1 | 2022 |
| 19 | Trulieve Cannabis Corp. SEC EDGAR DEF 14A, CIK 1754195 | $7.6M | $31K | 243:1 | 2025 |
| 20 | International Flavors & Fragrances Inc SEC EDGAR DEF 14A, CIK 51253 | $15.0M | $63K | 239:1 | 2025 |
| 21 | Zoetis Inc. SEC EDGAR DEF 14A, CIK 1555280 | $19.0M | $81K | 236:1 | 2025 |
| 22 | Dow Inc. Latest filing FY2023 SEC EDGAR DEF 14A, CIK 1751788 | $20.8M | $95K | 220:1 | 2023 |
| 23 | Idexx Laboratories Inc /de SEC EDGAR DEF 14A, CIK 874716 | - | - | 218:1 | 2025 |
| 24 | BeOne Medicines Ltd. SEC EDGAR DEF 14A, CIK 1651308 | $17.9M | $82K | 218:1 | 2025 |
| 25 | EDGEWELL PERSONAL CARE Co Latest filing FY2024 SEC EDGAR DEF 14A, CIK 1096752 | $9.8M | $49K | 198:1 | 2024 |
Latest filing: 11 of the 25 issuers above have no FY2025 filing on file, so their row shows their newest earlier year (see the FY column). They are ranked here beside FY2025 filers and each carries the marker; the Chemicals & Pharmaceuticals benchmark and the lead figures on this page use FY2025 filers only.
Showing the top 25 unique CIKs by pay ratio (each issuer's latest filing). 274 additional Chemicals & Pharmaceuticals issuers are on company pages and the national rankings · browse all.
Chemicals & Pharmaceuticals sits in the bottom third of SIC-2 industries by median CEO-to-worker pay ratio (42:1; #63 of 63). Open Keenova Therapeutics plc for the in-SIC filing next to this median, or compare every SIC on the Industries directory.
Read our methodology - how this data is sourced, computed, and verified.